What does Oryzon Genomics’ Japanese patent application cover?

The application covers combinations of iadademstat with immune checkpoint inhibitors, including PD-1/PD-L1 inhibitors such as atezolizumab and durvalumab, for cancer therapy.

What is the status of Oryzon Genomics’ Japanese patent application?

The Japanese Patent Office has issued a Decision to Grant, but the patent remains subject to formal grant. Oryzon Genomics said that, following formal grant, it is expected to remain in force until at least 2040, excluding any available patent term extensions.

Where has Oryzon Genomics secured patent protection for iadademstat combinations?

Oryzon Genomics said it has secured patent protection for these combinations in Europe, Japan, Australia and Russia.

Are Oryzon Genomics’ corresponding patent applications still pending in other countries?

Yes. Oryzon Genomics said corresponding patent applications continue to be prosecuted in other countries.

How does Oryzon Genomics describe the purpose of the Japanese patent decision?

Neus Virgili, Oryzon Genomics’ Chief IP Officer, said the Japanese grant represents another milestone in building a robust patent portfolio around iadademstat and reinforces the company’s strategy to protect its clinical use in combination with immune checkpoint inhibitors.

What is iadademstat being evaluated for by Oryzon Genomics?

Oryzon Genomics is evaluating iadademstat in combination with PD-L1 inhibitors, specifically atezolizumab or durvalumab, in first-line, extensive-disease small cell lung cancer patients.

What clinical trial is evaluating Oryzon Genomics’ iadademstat combinations?

The combinations are being evaluated in an ongoing Phase I/II trial conducted and sponsored by the U.S. National Cancer Institute under a Cooperative Research and Development Agreement with Oryzon Genomics.

How broad is the clinical site network for Oryzon Genomics’ iadademstat trial?

Oryzon Genomics said the study is being carried out at more than 30 clinical sites across the United States.

Which institutions are involved in Oryzon Genomics’ iadademstat trial?

The company named Memorial Sloan Kettering Cancer Center, Johns Hopkins, City of Hope, Yale University and the University of Chicago among the participating cancer institutions.

What type of company is Oryzon Genomics?

Oryzon Genomics describes itself as a clinical-stage biopharmaceutical company and a global leader in epigenetics.

What share identifiers does Oryzon Genomics provide in the announcement?

Oryzon Genomics provides ISIN Code: ES0167733015 and the symbol ORY.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon receives Japanese decision to grant iadademstat combination patent

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon receives Japanese decision to grant iadademstat combination patent

Published Monday, 22 December 2025

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Regulatory approval
Published: Monday, 22 December 2025
Source announcement: oryzon.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced a Japanese Patent Office Decision to Grant for iadademstat combinations.

Patent application JP2021-557187 covers combinations of iadademstat with PD-1/PD-L1 inhibitors.
After formal grant, protection is expected until at least 2040, excluding available extensions.
Protection is secured in Europe, Japan, Australia and Russia; applications continue elsewhere.

NCI sponsors an ongoing Phase I/II SCLC trial under a CRADA with Oryzon.

Investor FAQs

Oryzon Genomics announced that the Japanese Patent Office had issued a Decision to Grant for patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON expands global patent protection for iadademstat with grant decision in Japan covering combinations with PD-1/PD-L1 inhibitors
Published: Monday, 22 December 2025
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…